Your browser doesn't support javascript.
loading
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Mateo, Joaquin; Porta, Nuria; Bianchini, Diletta; McGovern, Ursula; Elliott, Tony; Jones, Robert; Syndikus, Isabel; Ralph, Christy; Jain, Suneil; Varughese, Mohini; Parikh, Omi; Crabb, Simon; Robinson, Angus; McLaren, Duncan; Birtle, Alison; Tanguay, Jacob; Miranda, Susana; Figueiredo, Ines; Seed, George; Bertan, Claudia; Flohr, Penny; Ebbs, Berni; Rescigno, Pasquale; Fowler, Gemma; Ferreira, Ana; Riisnaes, Ruth; Pereira, Rita; Curcean, Andra; Chandler, Robert; Clarke, Matthew; Gurel, Bora; Crespo, Mateus; Nava Rodrigues, Daniel; Sandhu, Shahneen; Espinasse, Aude; Chatfield, Peter; Tunariu, Nina; Yuan, Wei; Hall, Emma; Carreira, Suzanne; de Bono, Johann S.
Afiliação
  • Mateo J; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Porta N; The Institute of Cancer Research, London, UK.
  • Bianchini D; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
  • McGovern U; University College Hospital, University College London Hospitals NHS Foundation Trust, London, UK.
  • Elliott T; The Christie NHS Foundation Trust, Manchester, UK.
  • Jones R; University of Glasgow and Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Syndikus I; The Clatterbridge Cancer Centre, Wirral, UK.
  • Ralph C; St James's Institute of Oncology, University of Leeds, Leeds, UK.
  • Jain S; Queen's University, Belfast, UK.
  • Varughese M; Musgrove Park Hospital, Taunton, UK.
  • Parikh O; Royal Blackburn Hospital, Blackburn, UK.
  • Crabb S; University of Southampton, Southampton, UK.
  • Robinson A; Royal Sussex County Hospital, Brighton, UK.
  • McLaren D; Western General Hospital, Edinburgh, UK.
  • Birtle A; Royal Lancaster Infirmary, Lancaster, UK.
  • Tanguay J; Velindre Cancer Centre, Cardiff, UK.
  • Miranda S; The Institute of Cancer Research, London, UK.
  • Figueiredo I; The Institute of Cancer Research, London, UK.
  • Seed G; The Institute of Cancer Research, London, UK.
  • Bertan C; The Institute of Cancer Research, London, UK.
  • Flohr P; The Institute of Cancer Research, London, UK.
  • Ebbs B; The Institute of Cancer Research, London, UK.
  • Rescigno P; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
  • Fowler G; The Institute of Cancer Research, London, UK.
  • Ferreira A; The Institute of Cancer Research, London, UK.
  • Riisnaes R; The Institute of Cancer Research, London, UK.
  • Pereira R; The Institute of Cancer Research, London, UK.
  • Curcean A; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
  • Chandler R; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
  • Clarke M; The Institute of Cancer Research, London, UK.
  • Gurel B; The Institute of Cancer Research, London, UK.
  • Crespo M; The Institute of Cancer Research, London, UK.
  • Nava Rodrigues D; The Institute of Cancer Research, London, UK.
  • Sandhu S; Peter McCallum Cancer Center, Melbourne, VIC, Australia.
  • Espinasse A; The Institute of Cancer Research, London, UK.
  • Chatfield P; The Institute of Cancer Research, London, UK.
  • Tunariu N; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
  • Yuan W; The Institute of Cancer Research, London, UK.
  • Hall E; The Institute of Cancer Research, London, UK.
  • Carreira S; The Institute of Cancer Research, London, UK.
  • de Bono JS; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: johann.de-bono@icr.ac.uk.
Lancet Oncol ; 21(1): 162-174, 2020 01.
Article em En | MEDLINE | ID: mdl-31806540
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Biomarcadores Tumorais / Enzimas Reparadoras do DNA / Neoplasias de Próstata Resistentes à Castração / Inibidores de Poli(ADP-Ribose) Polimerases / Mutação Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Biomarcadores Tumorais / Enzimas Reparadoras do DNA / Neoplasias de Próstata Resistentes à Castração / Inibidores de Poli(ADP-Ribose) Polimerases / Mutação Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article